Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 144
- Registration Number
- NCT02932436
- Locations
- 🇩🇪
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention, Mainz, Germany
Cardiovascular Effects of Empagliflozine
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Tel Aviv University
- Target Recruit Count
- 10
- Registration Number
- NCT02918591
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Henrik Enghusen Poulsen
- Target Recruit Count
- 31
- Registration Number
- NCT02890745
- Locations
- 🇩🇰
Center for Diabetes Research, Gentofte Hospital, Hellerup, Denmark
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 88
- Registration Number
- NCT02874807
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333580
- Registration Number
- NCT02864914
- Locations
- 🇬🇧
RTI health solutions, One Or Multiple Sites, United Kingdom
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 822
- Registration Number
- NCT02863328
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02833415
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 68
- Registration Number
- NCT02798744
- Locations
- 🇬🇧
Leicester Diabetes Centre, Leicester, United Kingdom
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 24
- Registration Number
- NCT02792400
- Locations
- 🇩🇰
Center for Diabetes Research, Gentofte Hospital, Copenhagen University, Hellerup, Denmark
Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02782624
- Locations
- 🇩🇪
1276.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.